We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Genmab (GMAB – Research Report), with a price target ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objec ...

GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...

Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...

Genmab A/S (Nasdaq: GMAB) held its Annual General Meeting, today at the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting, Deirdre P. Connelly, Chair of the Board of Directors gave – on ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...